±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 516  |  »Ø¸´: 3
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

ÙóÓî΢·ç

³¬¼¶°æÖ÷

ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡

[ÇóÖú] Çë½Ì΢¹Üµ°°×ʵÑé

tubulin protein assay
Õâ¸öʵÑéÔõô×ö°¡¡£¿´µÄÒ»¸öAMµÄÎÄÕÂ×öµÄ¼ì²âPTXµÄʵÑ飬ÓÐЩ²»Ã÷¡£Çó½Ì¡£
Relative activities of PTX were estimated by calculating the maximum rate of tubulin
protein polymerization relative to the standard samples (Figure S5). Stabilities of the free and
encapsulated PTX inside different types of NCs were evaluated by measuring the variations of
their activities using the tubulin assay after storage at 25 ¡ãC and 37 ¡ãC for 1¨C14 d in 96-well
microtiter plates according to previously established protocols. Briefly, at defined time
intervals, NCs were separated using centrifugation and redispersed in water at pH 4.5 to
extract PTX from NCs, and then PTX was separated using HPLC to perform a tubulin protein
assay. Then, select concentrations of PTX were reacted with tubulin protein solution (general
tubulin buffer, tubulin glycerol buffer, 1  mM GTP), and the reaction was followed by
measuring the increase in apparent absorption at 350 nm over a 1 h period at 37 ¡ãC using an
ELISA plate reader (Safire II, Tecan Sales Switzerland AG, Mannedorf, CH).  
As shown in Figure S5, drug degradation is generally considered as a first order process
and can be described by the following equation: ln(a/a0) = kt, where a is the activity of drug
at time t, a0 is the initial drug activity, k is the degradation rate constant. At half-life of drug
(t1/2), we have a=a0/2 =>  t1/2= 0.693/k => k=0.693/t1/2. The results of PTX half-life (t1/2) and
degradation rate constant (k) are shown in Figure S6 and Figure 3(a), respectively.
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

xueqi95

°æÖ÷

ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡

Â¥Ö÷£¬ÇëÎÊÄãÓõÄ΢¹Üµ°°×ÊÇ´ÓÄÄÀïÂòµÄ£¿
4Â¥2015-04-11 10:10:04
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 4 ¸ö»Ø´ð

DEARGUI

ר¼Ò¹ËÎÊ

ÄÑ

[ ·¢×ÔСľ³æ¿Í»§¶Ë ]
2Â¥2014-08-19 19:58:42
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 273Çóµ÷¼Á +18 ÀîÜÆÐÂ1 2026-03-31 18/900 2026-04-01 19:12 by ¸üºÃµÄÌÉÆ½
[¿¼ÑÐ] 266·Ö£¬Ò»Ö¾Ô¸µçÆø¹¤³Ì£¬±¾¿Æ²ÄÁÏ£¬Çó²ÄÁÏרҵµ÷¼Á +6 ÍÛºôºßºôºß 2026-04-01 7/350 2026-04-01 19:11 by 549790059
[¿¼ÑÐ] »¯Ñ§¹¤³Ìר˶324·Ö£¬Ò»Ö¾Ô¸Öйú¿óÒµ´óѧÇóµ÷¼Á +3 ¹¢¹¢1314 2026-04-01 3/150 2026-04-01 19:04 by CFQZAFU
[¿¼ÑÐ] 362Çóµ÷¼Á +13 Î÷ÄϽ»²ÄÁÏר˶3 2026-03-31 13/650 2026-04-01 17:38 by JYD2011
[¿¼ÑÐ] 342Çóµ÷¼Á +10 Mary Keen 2026-03-28 11/550 2026-04-01 17:24 by xhai2011
[¿¼ÑÐ] ÕÒµ÷¼Á +5 ³þÇÇÇÇ 2026-04-01 5/250 2026-04-01 16:12 by w³æ³æ123
[¿¼ÑÐ] 085600£¬²ÄÁÏÓ뻯¹¤321·Ö£¬Çóµ÷¼Á +11 ´ó²öС×Ó 2026-03-27 11/550 2026-04-01 16:10 by cymywx
[¿¼ÑÐ] ÉúÎïѧ 296 Çóµ÷¼Á +9 ¶ä¶ä- 2026-03-26 11/550 2026-04-01 14:44 by Çóµ÷¼Ázz
[¿¼ÑÐ] 330·ÖÇóµ÷¼Á +11 qzenlc 2026-03-29 11/550 2026-04-01 14:32 by chenqifeng666
[¿¼ÑÐ] һ־Ըͬ¼Ã´óѧ323·Ö£¨080500£©Çóµ÷¼Á +4 yikeniu 2026-04-01 4/200 2026-04-01 14:06 by asdfzly
[¿¼ÑÐ] 262Çóµ÷¼Á +9 ÀøÖ¾Ò»¶¨·¢ÎÄÕ 2026-03-31 10/500 2026-04-01 12:22 by sunshine0013
[¿¼ÑÐ] 291Çóµ÷¼Á +3 ÃÔÃÉľľ 2026-04-01 4/200 2026-04-01 11:07 by ÄæË®³Ë·ç
[¿¼ÑÐ] 288×ÊÔ´Óë»·¾³×¨Ë¶Çóµ÷¼Á£¬²»ÏÞרҵ£¬ÓÐѧÉϾÍÐÐ +25 lllllos 2026-03-30 26/1300 2026-04-01 09:52 by Ò»Ö»ºÃ¹û×Ó?
[¿¼ÑÐ] 322Çóµ÷¼Á +4 ìäÙÒXX 2026-03-31 4/200 2026-04-01 08:21 by JourneyLucky
[¿¼ÑÐ] ÕÅ·¼Ãú-Öйúũҵ´óѧ-»·¾³¹¤³Ìר˶-298 +9 ÊÖ»úÓû§ 2026-03-26 9/450 2026-03-31 18:09 by 544594351
[¿¼ÑÐ] ²ÄÁÏÇóµ÷¼Á Ò»Ö¾Ô¸¹þ¹¤´ó×Ü·Ö298·Ö£¬Ç°Èý¿Æ223·Ö +11 dongfang59 2026-03-27 11/550 2026-03-31 16:51 by Wang200018
[¿¼ÑÐ] 315Çóµ÷¼Á +6 akie... 2026-03-28 7/350 2026-03-31 16:48 by asdfzly
[¿¼ÑÐ] Çóµ÷¼Á +7 ÕùÈ¡¾Åµã˯ 2026-03-28 8/400 2026-03-28 21:07 by ÕùÈ¡¾Åµã˯
[¿¼ÑÐ] 081200-314 +3 LILIQQ 2026-03-27 4/200 2026-03-28 09:41 by ±£»¤µØÇòÄãÎÒ×öÆ
[¿¼ÑÐ] ¸´ÊÔµ÷¼Á£¬Ò»Ö¾Ô¸ÄÏÅ©083200ʳƷ¿ÆÑ§Ó빤³Ì +5 XQTJZ 2026-03-26 5/250 2026-03-27 14:49 by ¿ñìÅÂóµ±µ±
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û